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Objective: To evaluate the clinical implementation of pharmacotherapy recommendations
for chronic obstructive pulmonary disease (COPD) based on the Global Initiative for chronic
obstructive lung disease (GOLD) guidelines, in a longitudinal setting.
Methods: This is a sub-analysis of a prospective, non-interventional cohort study including
patients with confirmed mild-to-very-severe COPD from seven pulmonary outpatient clinics
in Switzerland. Follow-up visits took place annually for up to 7 years, from October 2010
until December 2016. For each visit, we evaluated the compliance of the prescribed phar-
macotherapy with the concurrently valid GOLD guideline. We investigated whether step-ups
or step-downs in GOLD stage or risk-group were accompanied by concordant changes in
prescribed medication. Groups were compared via ANOVA.
Results: Data of 305 patients (62±7 years, 66% men) were analysed. In 59.1% of visits, the
prescribed medication conformed to the respective valid GOLD-guideline. Patients with very
severe COPD were most likely to receive pharmacotherapy in compliance with guidelines.
Step-ups and step-downs in risk group, requiring escalation, or de-escalation of pharma-
cotherapy, were noticed in 24 and 43 follow-up visits, respectively. Step-ups were adequately
implemented in 4 (16.7%) and step-downs in six cases (14.0%).
Conclusion: The compliance of COPD-pharmacotherapy with GOLD-guidelines is subop-
timal, especially in lower risk groups. The high rates of missed out treatment-adjustments
suggest that the familiarity of physicians with guidelines leaves room for improvement.
Keywords: chronic obstructive pulmonary disease, Global Initiative for Chronic Obstructive
Lung Disease guidelines, guideline-compliance
Plain Language Summary
Treatment of chronic obstructive lung disease (COPD) in line with the recommendations of the
Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline has been shown to
improve the patient’s quality of life and to decrease healthcare costs. However, the compliance of
prescribed pharmacotherapy to GOLD guidelines appears to be suboptimal, according to cross-
sectional studies. We evaluated the conformity of pharmacotherapy with GOLD guidelines in
a longitudinal study, investigating a Swiss cohort of patients with COPD. We found the pharma-
cotherapy regimens in our cohort to be only partially compliant with guidelines, most commonly
due to overtreatment with inhaled corticosteroids, but also overtreatment with or a lack of
bronchodilator-treatment was observed frequently. Furthermore, longitudinal changes in therapy-
regimens that would had been necessary according to GOLD guidelines were rarely implemented
correctly. We, therefore, conclude that the guideline-conformity of COPD treatment yet leaves
considerable room for improvement, in order to achieve optimal symptom reduction in each patient.
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Introduction
Chronic obstructive pulmonary disease (COPD), with
a global prevalence of approximately 11.7%, is considered
the fourth leading cause of death worldwide.1,2 COPD is
associated with a significant economic burden, producing
annual costs of nearly 50 billion Euros in the European
Union.3 The Global Initiative for Chronic Obstructive Lung
Disease (GOLD) strategy-guideline aims for the inclusion of
concurrent therapy recommendations in clinical practice.
Optimal pharmacological treatment of patients with COPD
can improve symptoms,4–7 exercise capacity,4,6 health
status,8 and reduces exacerbations.9,10 Accordingly, optimal
implementation of GOLD-guidelines in clinical practice has
been shown to significantly decrease healthcare costs.11
Whereas a lack in pharmacotherapy might impair patient
and healthcare outcomes, overtreatment should be avoided
as well. Especially indications for inhaled corticosteroids
(ICS) have become fewer, due to their unfavourable cost-
benefit-ratio, with regards to serious adverse events and the
superior effectiveness of long-acting bronchodilators (BD) in
decreasing exacerbations.12 Despite the beneficial outcomes
associated with guideline-complying therapy, various cross-
sectional studies showed GOLD-implementation to be sub-
optimal, presumably due to poor familiarity of physicians
with guidelines.13–15 Additionally, substantial changes in
GOLD reports published throughout the years, such as the
introduction and modification of the »ABCD«-scheme in
2011 and 2017, possibly impair clinician’s familiarity with
the recommendations even more. Yet, due to the progressive
nature of COPD, treatment regimens have to be re-evaluated
at least annually.16 However, knowledge of the clinical rea-
lisation of recommended therapy adjustments in longitudinal
settings is mostly lacking.
The aim of this study was to evaluate the clinical
implementation of recommendations for pharmacotherapy
and pharmacotherapy-adjustments based on GOLD-




This is a sub-analysis of the prospective, non-interventional
cohort study 'The Obstructive Pulmonary Disease Outcomes
Cohort Study (TOPDOCS)'. Patients with COPD from seven
pulmonary outpatient clinics in Switzerland were included in
the cohort during outpatient visits or hospital stays. Follow-up
visits took place annually for up to 7 years, fromOctober 2010
until December 2016, within a mean follow-up period of 2.03
years. Patients with confirmed mild-to-very-severe COPD
were eligible. Exclusion criteria were mental constraint dis-
abling the patient to give written informed consent and to
comply with the study instructions, respectively. The Ethics
Committee of Zurich approved the study (EK-ZH-NR: 1734
and 2011–0106), which was conducted in accordance with the
declaration of Helsinki and which was registered at www.
ClinicalTrials.gov, NCT01527773.
Measurements
The following factors were assessed annually.
Comorbidities, Symptoms and Health Status
Interviews, clinical examinations, and reviews of the med-
ical history were performed. COPD-associated symptoms
and their impact on health were evaluated by means of
COPD Assessment testing (CAT).17 The severity of dys-
pnoea was assessed with the help of the modified medical
research council (mMRC) scale.18 Acute exacerbations
(AE) were defined as an increase in dyspnoea, cough
and/or sputum production, requiring treatment with anti-
biotics and/or oral corticosteroids. Participants were clas-
sified as frequent exacerbators when at least two-, and as
infrequent exacerbators when less exacerbations occurred
during the respective previous year.
Respiratory Variables
Forced expiratory volume in one second (FEV1), residual
volume to total lung capacity (RV/TLC), and diffusing
capacity of the lung for carbon monoxide (DLco) were
measured after bronchodilation within a standard pulmon-
ary functioning test, performed in accordance with guide-
lines of the American Thoracic Society and the European
Respiratory Society.19,20 Participants were categorised into
GOLD stages (I–IV), and risk groups (A-D) consistent with
the respective concurrent guideline at each visit.12,21,22
Medication and Accordance with Guidelines
For each visit, we evaluated the conformity of prescribed
pharmacotherapy with the respective, concurrently valid
GOLD guideline. The study started in 2010; thus, the valid
guideline for the 2010 visits was the 2006 GOLD report.
Within the course of the trial, changes in guidelines with an
impact on treatment recommendations were published in the
2011 revision and the 2014 update.21,22 Identifying overtreat-
ment in line with the GOLD recommendation-table is quite
distinct (figure 5.3–7 in guideline 2007, figure 4.4 in guidelines
2011 and 2014).12,21,22For instance, patients in risk-groupAor
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B receiving ICS are clearly overtreated.However,more careful
considerations are required when defining undertreatment, as,
for example, GOLD A patients who do not receive medical
treatment are not necessarily undertreated. According to
GOLD, a lack of bronchodilator (BD) treatment is only present
when the patient receives no such drug despite being sympto-
matic. Therefore, only symptomatic patients (mMRC-score≥2
or CAT-score≥10) who did not receive an inhaled BD were
classified undertreated. The 2006 report recommends adding
ICS in patientswithGOLD stage III and IV,who have repeated
exacerbations; thus, these criteria were adopted for defining
ICS undertreatment in visits before 2011. In line with GOLD
2011 and 2014, from 2011 on, patients not receiving ICS were
defined as ICS undertreated when they were categorised
GOLD stage III or IV and had exacerbations frequently (≥2 -
per year), despite treatmentwith long-actingBDs. The absence
of roflumilast was not rated as undertreatment, since the
recommendation for this agent is rather weak. GOLD-2011
and 2014 state that it may be added in stage III or IV patients
with frequent exacerbations that are not adequately controlled
by long-acting BDs. However, roflumilast prescribed to
patients with GOLD stage I or II was defined as overtreatment
from 2011 on.
Changes in Recommended Medication Over Time
and Influence of Guideline Changes
We investigated whether step-ups or step-downs in GOLD
stage or risk-group were accompanied by adequate changes
in prescribed medication. Furthermore, we longitudinally
analysed individual changes in therapy-recommendations,
which were conditioned exclusively by guideline change.
Therefore, whenever a step-up or -down in risk-group was
noticed in a visit following a change in the guideline, the
respective recommendation was compared to what would
have been recommended in the former guideline, for the
specific case. Furthermore, we applied the categorisation cri-
teria from GOLD 2017 on our cohort for investigating the
impact of this guideline on individual treatment-suggestions.
In the 2017 GOLD report, the »ABCD«-system was signifi-
cantly modified, as airway obstruction was excluded from the
categorisation criteria.
Statistical Analysis
Descriptive statistics include mean and standard deviation
(SD) for normally distributed parameters, as well as median
and 25%/75%-quartiles for non-normally distributed vari-
ables. Categorical variables are shown as numbers and
percentages of the total. For continuous variables, groups
(correct treatment vs undertreatment vs overtreatment vs
varying treatment) were compared via ANOVA. For post-
hoc testing, one-way ANOVA was used. P-values were
Bonferroni corrected. Categorical variables were assessed
by Chi-squared test. A two-sided p-value of <0.05 was
considered to be statistically significant. We used STATA/
SE15.1 (StataCorp, College Station, TX, USA) for analysis.
Results
Participants
Three hundred and twenty-six patients initially gave con-
sent and data of 305 participants (726 study-visits) were




A 8.8% of visits fell under the scope of the 2006, 54.3% of
the 2011, and 36.9% of the 2014 GOLD-guidelines. In
326 COPD patients eligible and
agreed to take part
• Refused participation (47)
• Mental or physical disability (3)
• Language difficulties
precluding informed consent (6)
• No show up (21)
305 participants attended the first
visit
382 COPD patients screened
for eligibility
• Participants discontinued
203 participants attended the 2nd,
143 the 3rd, 50 the 4th, 18 the 5th,
5 the 6th, and 2 the 7th visit
Figure 1 Study flow. The decrease in the number of participants has several reasons:
the cohort-study was initially designed as a cross-sectional trial. During the course of
the first year, the design was changed to a longitudinal study intended to analyse the
course of lung function, exacerbations, cardiovascular outcomes, and further para-
meters over a period of 3 years. The participants gave consent to only one study visit
initially and, when asked again after the first year, a great number of participants did not
agree to taking part in a 3-year-study. Then again, after 3 years, the study period was
extended and only a part of the participants agreed to continue. Additionally, parts of
the initial COPD-cohort had died within the study period.
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59.1% of visits, the prescribed medication conformed to the
concurrent recommendations, 61.8% and 59.0% before and
after the introduction of risk-groups in 2011, respectively.
GOLD non-compliant therapy was due to overtreatment
with ICS in 40.7%, with long-acting BD in 9.8%, with ICS
and long-acting BD in 1.5%, and due to undertreatment with
ICS, BD, or ICS and long-acting BD, in 17.1%, 16.7%, and
1.5% of cases, respectively. The distribution of pharma-
cotherapies and the accordance with GOLD-guidelines are
shown before and after the introduction of symptom-based
categories in 2011 (Tables 2 and 3, Figure 2A and B).
Adjustments of Treatment Regimens to
Worsening of COPD and Guideline-Change
Step-ups and -downs in risk-category requiring escalation, or
de-escalation of pharmacotherapy were noticed in 24, and 43
follow-up visits, respectively. Steps-ups were adequately
implemented in 4 (16.7%), steps down in 6 cases (14.0%),
after a mean period of 1.1 visits. Participants whose therapy
was adjusted in line with recommendations were categorised
risk-group A in 30%, B in 20%, C in 10%, and D in 40%.
Cases in which adequate therapy-adjustments weremissed out
were followed for 1.6 visits in mean. None of the observed
steps occurred exclusively due to a change in the guideline.
However, when categorising our cohort after the GOLD-
2017-criteria, 44.20% of participants would be shifted from
group D to B, and 6.2% from group C to A or B.
Comparison of Characteristics Between
Groups
A comparison of characteristics between participants who
were correctly-, under-, over-, or variably treated throughout
all visits can be seen in Table 4. The group of steadily
undertreated participants had a significantly higher body-
mass-index (BMI), and contained the largest amount of
smokers, when compared with the rest of the cohort.
Compliantly treated participants had the significantly highest
mMRC and CATscores, lowest FEV1 and DLco and highest
RV/TLC values of all groups. Among under- and overtreated
Table 1 Baseline Characteristics
Clinical Characteristics
Age, years 62.3 (7.3)
Male, n/total (%) 201/305 (65.90%)
BMI, kg/m2 26 (22.5/29.4)
Smoker, n/total (%) 231/305 (75.74%)
Pack years, n 40 (30/60)
GOLD stage 1, n/total (%) 26/305 (8.52%)
GOLD stage 2, n/total (%) 100/305 (32.79%)
GOLD stage 3, n/total (%) 111/305 (36.39%)
GOLD stage 4, n/total (%) 68/305 (22.30%)
mMRC-Score, n 1.73 (1.06)
CAT-Score, n 16 (7.24)
FEV1 post dilatation, % predicted 44 (31/64.2)
RV/TLC, % predicted 55.27 (11.84)
DLCO (Hb), % predicted 47 (35/68)
Exacerbations in previous year, n 1 (0/2)
Exacerbations in previous year leading to
hospitalisation, n
0 (0/0)
Frequent exacerbator, n/total (%) 77/305 (25.25%)
Notes: Values are presented as Mean (SD) or Median (IQR), unless stated otherwise.
Abbreviations: BMI, Body Mass Index; GOLD, Global Initiative for Obstructive
Lung Disease; mMRC, Modified British Medical Research Council; CAT, Chronic
Obstructive Pulmonary Disease Assessment Test; FEV1, Forced expiratory volume
in 1 second; RV/TLC, Residual volume/total lung capacity; DLCO (Hb), Carbon
monoxide diffusion capacity for haemoglobin concentration.
Table 2 Overview on Medication of the Cohort, and
Accordance with 2006 GOLD Guideline (Visits That Took
Place Before 2011)
GOLD Stage I II III IV
Prescribed medication of cohort
No treatment 57.1% 52.9% 4.8% 0.0%
LAMA 28.6% 5.9% 4.8% 5.0%
LAMA+ICS 0.0% 0.0% 4.8% 5.0%
LABA+ICS 14.3% 17.6% 4.8% 5.0%
LAMA+LABA 0.0% 0.0% 4.8% 5.0%
LAMA+LABA+ICS 0.0% 23.5% 66.7% 70.0%
LABA+ICS+THEO 0.0% 0.0% 4.8% 5.0%
LAMA+LABA+ICS+THEO 0.0% 0.0% 4.8% 5.0%
% of total visits 10.8% 26.2% 32.3% 30.8%
Accordance with GOLD 2006
% treatment according to
guideline
25% 33.3% 78.6% 85.7%
Undertreatment
Short-acting BD 25% 0.0% 0.0% 0.0%
Short and long-acting BD 0.0% 33.3% 0.0% 0.0%
ICS 0.0% 0.0% 0.0% 14.3%
Overtreatment
Long-acting BD 50% 0.0% 0.0% 0.0%
ICS 0.0% 22.2% 21.4% 0.0%
Long-acting BD and ICS 0.0% 11.1% 0.0% 0.0%
Notes: Values are presented as percentage of the respective stage of disease,
separately for the prescribed medicine, and the accordance with guidelines,
respectively.
Abbreviations: GOLD, Global Initiative for Chronic Obstructive Lung Disease;
SABA, short-acting β2-receptor agonist; LAMA, long-acting muscarinic antagonist;
ICS, inhaled corticosteroid; LABA, long-acting β2-receptor agonist; ROFL,
Roflumilast; THEO, Theophylline; BD, Bronchodilator.
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participants, there were significantly less frequent exacerba-
tors, when compared with the correctly treated patients.
Discussion
This study evaluated the conformity of COPD-
pharmacotherapy and therapy adjustments, with GOLD
guidelines. To our knowledge, no previous trial classified
under- and overtreatment-categories in this detail. We
found that the prescribed medications were only partially
compliant with guidelines. Furthermore, required escala-
tions and de-escalations of pharmacotherapy were inade-
quately realised. Patients with more severe COPD were
more likely to be treated in accordance with guidelines.
Whereas COPD is not curable, it is yet a treatable condi-
tion. Pharmacological treatment is a fundamental component
of COPD therapy, as it has been shown to improve the
patient’s quality of life,23 when administered in accordance
with treatment recommendations. However, previous studies
suggested discrepancies between prescribed medication and
guideline-propositions. The rather low rate of guideline-
adherent therapy prescribed in our cohort (59.1%) is in line
with the results of earlier studies.14,24 Factors that might
explain the low conformity-rates, next to inadequate familiar-
ity with guidelines, might be time-constraints or low self-
efficacy of physicians.25 Educational interventions to improve
physician’s familiarity with guidelines have been shown to be
successful; thus, their utilisation should be further
promoted.25,26 In this study, ICS over-prescription was the
most common reason for guideline non-compliance. This
finding is quite alarming, as serious side-effects of ICS, such
as pneumonia, could be avoided.27 Especially in combination
with long-acting muscarinic antagonists (LAMA) and long-
acting β2-receptor agonists (LABA), ICS over-prescription
was observed in other populations with COPD as well.14,28
Inhaled BDs are effective in reducing dyspnoea and exacer-
bations, and they show a comparably favourable tolerability
over ICS. However, particularly cardiac arrhythmia and tre-
mor are adverse effects that have to be taken into account
when prescribing inhaled BDs without impeccable indica-
tions. Nevertheless, we also found large amounts of patients
that were BD-undertreated. Due to their alleviating effects on
dyspnoea and their potential to reduce exacerbations, treat-
ment with BDs is of central importance in COPD.16,29 Yet,
with regard to our results, the rate of patients treated with
inhaled BDs is improvable.
Required escalations, or de-escalations in pharmacother-
apy were rarely implemented correctly within our cohort.
This finding calls into question the physician’s familiarity
with guidelines and their routine in classifying disease sever-
ity and establishing treatment regimens. In a survey reported
by Palmiotti et al,14 60% of pulmonologists stated that the
categorisation into the »ABCD«-groups was cumbersome in
clinical practice, as performing spirometry at each visit
would take too long. However, the conformity of prescribed
Table 3 Overview on Medication of the Cohort, and
Accordance with GOLD 2011/2014 (Visits from 2011 on)
Risk Group A B C D
Prescribed medication of cohort
No treatment 43.8% 29.2% 3.8% 2.3%
SABA 6.9% 1.2% 1.7% 0.3%
LAMA 11.5% 17.6% 5.1% 2.8%
LAMA+ICS 0.0% 0.0% 0.0% 1.2%
LABA 3.8% 4.7% 1.7% 0.6%
LABA+ICS 13.1% 15.9% 15.3% 9.8%
LAMA+LABA 6.2% 5.9% 16.9% 8.3%
LAMA+LABA+ICS 13.8% 28.2% 45.8% 63.5%
LAMA+ICS+ROFL 0.0% 0.0% 0.0% 0.6%
LAMA+LABA+ROFL 0.0% 0.6% 0.0% 0.6%
LAMA+LABA+ICS+ROFL 0.8% 2.4% 3.4% 9.2%
LABA+ICS+THEO 0.0% 0.6% 0.0% 0.6%
LAMA+LABA+THEO 0.0% 0.0% 0.0% 0.3%
LAMA+LABA+ICS+THEO 0.0% 0.6% 1.7% 1.2%
% of total visits 19% 24.8% 8.6% 47.6%
Accordance with GOLD 2011/14
%treatment according to
guideline
65.9% 30.0% 38.6% 76.1%
Undertreatment
BD 0.0% 22.4% 0.0% 0.0%
ICS 0.0% 0.0% 14.0% 11.7%
Long-acting BD and ICS 0.0% 0.0% 0.0% 1.2%
Overtreatment
Long-acting BD 9.4% 0.0% 28.1% 0.0%
GC 20.0% 45.3% 5.3% 0.0%
Long-acting BD and ICS 3.5% 0.0% 0.0% 0.0%
ROFL 0.0% 0.6% 0.0% 0.0%
Overtreatment, categories not
applicable
1.2% 1.8% 14.0% 9.8%
Other
Incorrect treatment, over or
undertreatment not applicable
0.0% 0.0% 0.0% 0.6%
Notes: Values are presented as percentage of the respective stage of the disease,
separately for the prescribed medicine, and the accordance with guidelines,
respectively.
Abbreviations: GOLD, Global Initiative for Chronic Obstructive Lung Disease;
SABA, short-acting β2-receptor agonist; LAMA, long-acting muscarinic antagonist;
ICS, inhaled corticosteroid; LABA, long-acting β2-receptor agonist; ROFL,
Roflumilast; THEO, Theophylline; BD, Bronchodilator.
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medication with guidelines was similar before and after the
introduction of the »ABCD«-system in our cohort. Further
changes in GOLD-guidelines that were published within our
follow-up period had no effects on the individual treatment
recommendations of our cohort. Nevertheless, fundamental
changes in patient categorisation were published in the 2017
GOLD report, where disease-severity assessed by spirometry
was excluded from the »ABCD«-classification-criteria. In
line with the results of Cabrera López et al,30 the majority
of participants in our study would have been shifted into






























































Correct treatment Undertreatment Overtreatment
A
B
Figure 2 Distribution of prescribed medication and accordance with guidelines. (A) By risk-category: distribution of prescribed medicine. Nineteen percent of participants were
categorised group A, 24.8% B, 8.6% C, and 47.6%D. Visits, in which the patient had nomedication were not depicted in (A) due to clarity reasons. (B) By GOLD-stage (visits before
2011), or risk-category (visits from 2011 on): amount of visits where correct treatment, undertreatment, and overtreatment was observed. In visits before 2011, 12% of patients
were GOLD-stage 1, 26% stage 2, 41% stage 3, and 21% stage 4. In visits from 2011 on, 19% of participants were categorised group A, 24.8% B, 8.6% C, and 47.6% D.
Abbreviations: SABA, short-acting β2-receptor agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; LABA, long-acting β2-receptor agonist;
ROFL, Roflumilast; THEO, Theophylline; BD, Bronchodilator.
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other groups with application of the GOLD 2017-system,
mostly from groups C to A or B, and group D to B. This re-
classification causes even greater amounts of patients to be
overtreated with ICS. In connection with the low rates of
correctly performed therapy adjustments noticed in our
cohort, this result suggests that great amounts of patients
are still ICS overtreated in 2019. However, whether ICS
therapy should be discontinued in these patients is currently
under discussion, since ICS withdrawal might be associated
with increases in symptoms and exacerbations.16
We observed that patients who were undertreated
throughout all study-visits, had the significantly highest
BMI, when compared with the rest of the cohort. We assume
that in more obese patients, COPD-severity is likely to be
underrated, as overweight itself is a prevalent cause of dys-
pnoea and wheezing.31 Thus, physicians might underesti-
mate the actual need for COPD-treatment in obese patients.
The comparably large amount of smokers within the under-
treated group may be a result of these patients' lower therapy
motivations. Besides that, the physician in charge might
prompt patients to stop smoking before further escalating
pharmacotherapy. Participants treated in compliance with
guidelines were most likely to have worse symptom-scores,
lung function parameters, and frequent exacerbations.
Furthermore, group D-patients were most likely to be treated
guideline-compliantly in our study. Accordingly, in a COPD-
cohort in Hong Kong, correctly treated patients had more
exacerbations when compared with under- and overtreated
groups.24 We, therefore, presume that firstly, due to their
increased symptoms and exacerbations, patients with more
severe COPD have a higher probability to be treated in
hospitals, and therefore by specialists. Secondly, these
patients experience more disease burden, and therefore
might put more effort into their own therapy. Lastly, GOLD-
guidelines offer the greatest amount of combinations for
medical therapy in risk-group D, thereby increasing the
chance to administer a correct treatment.
A limitation of our study is that we did not collect data
on the respective physician in charge. Secondly, since the
termination of the investigated follow-up-period, impor-
tant changes in GOLD-guidelines have been published.
Nevertheless, our main outcome was the guideline-
conformity of therapy-adjustments, which presumably
has not changed since 2016. Thirdly, we cannot be sure
if every participant had seen the respective physician in
charge once yearly, even if yearly follow-up is recom-
mended in GOLD-guidelines. Fourthly, the medication
prescribed is not necessarily identical to the medication
the patient actually is on. However, information on the
respective pharmacotherapy regimen of the individual par-
ticipants was acquired by asking the patients for the med-
ication they concurrently take. Lastly, we did not ask the
respective physicians in charge whether they followed
GOLD or other guidelines. Yet, our main outcome was
to investigate the accordance of COPD-pharmacotherapy
in Switzerland with the international state-of-the-art, rather
than the ability of the respective physicians in charge to
implement the guidelines they intended to follow.
Table 4 Comparison of Clinical Characteristics Between Groups










Median age, years 64 (58/69) 62 (54/68.5) 63 (52.67/68) 65.5 (61.5/70) 0.017
Median body-mass-index, kg/m2 24.2 (21.03/28.37) 28.6 (25.11/33.89)* 26.53 (23.2/28.72)† 26.035 (22.9/28.9)† <0.001
Female/male sex (%female) 57/104 (35.40%) 6/29 (17.14) 14/21 (40.00%) 27/47(36.49%) 0.149
Non-smoker/smoker at baseline (%
non-smoker)
130/31 (80.75%) 19/16* (54.29%) 25/10 (71.43%) 57/17† (77.03%) 0.010
Median mMRC-score, n 2 (1.5/3) 0 (1/1.5)* 1 (0.5/2)* 1 (1/2)* <0.001
Median CAT-score, n 18 (14/22) 12 (7/14.5)* 13 (7/19)* 13 (9/20)* <0.001
Median FEV1 post dilation, %
predicted
34 (25/43.5) 73 (55/82)* 61 (43/74)* 55.5 (43/69)*† <0.001
Median RV/TLC, % 62 (54/68) 42.75 (37/49)* 49 (41/58)* 51.87 (46/59.5)*† <0.001
Median DLco, mmol/kPa/min 36 (29/50) 72.5 (59/83.5)* 53 (38/69)*† 56.5 (41.5/71)*‡ <0.001
Frequent exacerbator at baseline, no/
yes (%no)
109/52 (67.70%) 33/2* (94.29%) 31/4* (88.57%) 55/19† (74.32%) 0.002
Notes: *p<0.05 vs “correct treatment”; †p<0.05 vs “undertreatment”, ‡p<0.05 vs “overtreatment”. Variables are presented as mean (SD) or Median (IQR) unless otherwise
stated.
Abbreviations: mMRC, Modified British Medical Research Council; CAT, chronic obstructive pulmonary disease Assessment Test; FEV1, Forced Expiratory Volume; RV,
Residual Volume; TLC, Total Lung Capacity; DLco, Diffusion factor of the Lung for Carbon Monoxide.
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In conclusion, we found only partial compliance of
COPD-pharmacotherapy with GOLD-guidelines.
Overtreatment with ICS appears to be the most common
therapeutic error, and it is an increased issue nowadays, as
indications for ICS have become fewer. However, also
undertreatment due to absence of inhaled BDs was fre-
quently noticed in our cohort. As BDs depict the backbone
of COPD treatment, enhancing the supply with these
agents should be focused. The poor guideline-conformity
of treatment-adjustments suggests that the familiarity of
physicians with guidelines is insufficient and leaves room
for improvement. Particularly pharmacotherapy of patients
in lower GOLD stages seems to be suboptimal and thus
requires more attention.
Abbreviations
BMI, Body Mass Index; CAT, Chronic Obstructive
Pulmonary Disease Assessment Test; COPD, Chronic
obstructive pulmonary disease; DLCO (Hb), Carbon mon-
oxide diffusion capacity for haemoglobin concentration;
FEV1, Forced expiratory volume in 1 second; GOLD,
Global Initiative for Chronic Obstructive Lung Disease;
ICS, Inhaled corticosteroid; LABA, Long-acting
β2-receptor agonists; LAMA, Long-acting muscarinic
antagonists; mMRC, Modified British Medical Research
Council; ROFL, Roflumilast; RV/TLC, Residual volume/
total lung capacity; SABA, Short-acting β2-receptor ago-
nists; THEO=Theophylline; TOPDOCS, The Obstructive
Pulmonary Disease Outcomes Cohort Study.
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